Tag Archives: CELG

Best Safest Stocks To Invest In 2019

Three minutes of frantic trading in Treasuries futures just offered a stark reminder of the danger of betting against the world’s safest asset.

What was shaping up as a second straight day of losses in Treasuries on Thursday, with 10-year yields threatening to hit the key psychological level of 3 percent, turned around in a hurry as turmoil in emerging markets spooked global investors.

Traders pointed to Brazilian officials’ unsuccessful efforts to stem the free-fall in their currency as the trigger for the wave of Treasuries buying. But the rush was magnified because investors were caught offside — there had been a dramatic increase in short bets against U.S. government debt in the past week.

The abruptness of the move, which drove yields on benchmark 10-year notes plunging as much as 9 basis points to 2.88 percent, was apparent in the futures market: From 1:33 p.m. New York time to 1:36 p.m., more than 100,000 contracts on 10-year futures changed hands. To put that in context, that’s more than the 80,000 that traded over a similar span at the time of Friday’s release of U.S. labor data.

Best Safest Stocks To Invest In 2019: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By George Budwell]

    Blood cancer drugs — even minor ones — are worth their weight in gold. Want proof? Celgene (NASDAQ:CELG) cut a deal with Impact Biomedicines earlier this year worth up to $7 billion for the myelofibrosis drug candidate fedratinib, even though the drug has a rather rocky clinical history.

  • [By Sean Williams]

    After months of crowing about the value this blue-chip biotech stock offered, I took the plunge and added Celgene (NASDAQ:CELG) to my portfolio.

    Image source: Getty Images.

  • [By Paul Ausick]

    Celgene Corp. (NASDAQ: CELG) traded down about 3.1% Monday and posted a new 52-week low of $84.22 after closing Friday at $86.89. The stock’s 52-week high is $147.17. Volume totaled around 6.4 million, less than 10% below the daily average of around 7 million. The company had no specific news.

Best Safest Stocks To Invest In 2019: LM Ericsson Telephone Company(ERIC)

Advisors’ Opinion:

  • [By David Zeiler]

    A study last year by Swedish networking equipment maker Ericsson (Nasdaq ADR: ERIC) estimated that new 5G-based opportunities could generate as much as $1.3 trillion in additional annual revenue by 2026 just for the carriers.

  • [By Lisa Levin]

    Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) shares were also up, gaining 18 percent to $7.86 after reporting strong Q1 results.

    Equities Trading DOWN

  • [By ]

    Companies at the top of the backbone buildout food chain included Cisco Systems (Nasdaq: CSCO), the scandalous and now-defunct Worldcom, Nokia (NYSE: NOK), Ericsson (Nasdaq: ERIC), and old-tech-turned-new-tech Corning (NYSE: GLW). I’ve owned, traded, and written about Corning in the past. It’s time to have another look.

Best Safest Stocks To Invest In 2019: Riverview Bancorp Inc(RVSB)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Charter Financial (NASDAQ: CHFN) and Riverview Bancorp (NASDAQ:RVSB) are both small-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

  • [By Ethan Ryder]

    Fj Capital Management LLC disclosed that they own 5.6% of Riverview Bancorp Inc (NASDAQ:RVSB) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Thursday, May 24th. The investor owns 1,273,912 shares of the stock valued at approximately $10,981,121. The reporting parties listed on the disclosure included Financial Opportunity Fund LLC, Financial Opportunity Long/Short Fund LLC, FJ Capital Management LLC and Martin S Friedman. The disclosure is available through EDGAR at this link.

Best Safest Stocks To Invest In 2019: SeaWorld Entertainment, Inc.(SEAS)

Advisors’ Opinion:

  • [By Evan Niu, CFA]

    Shares of SeaWorld Entertainment (NYSE:SEAS) have popped today, up by 10% as of 12:20 p.m. EDT, after the company reportedfirst-quarter earnings results. The company enjoyed strong gains in park attendance.

  • [By Rick Munarriz]

    Don’t look now, butSeaWorld Entertainment(NYSE:SEAS)is dousing short-sellers as if they were sitting in the Splash Zone at one of its killer whale shows. SeaWorld stock soared 15% last week, taking off after analysts at Wells Fargo and Stifel put out bullish notes. SeaWorld also announced the hiring an outsider as its chief strategy officer. The stock is trading at its highest level in more than two years, notching another new high-water mark this morning.

  • [By Max Byerly]

    SeaWorld Parks & Entertainment (NYSE: SEAS) and Vail Resorts (NYSE:MTN) are both consumer discretionary companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

  • [By Rick Munarriz]

    Area schools are letting out, so it’s not just the temperatures that are starting to heat up in Central Florida. Disney(NYSE:DIS), Universal Orlando parent Comcast (NASDAQ:CMCSA), and SeaWorld Entertainment (NYSE:SEAS) are starting to widen their operating schedules in anticipation of a healthy flow of tourists during the peak summer season.

  • [By Rick Munarriz]

    We now have the quarterly updates for all five of the country’s leading theme park and regional amusement park operators, and it’s safe to say the first three months of 2018 blew out the same three-month period of 2017. Six Flags (NYSE:SIX), Cedar Fair(NYSE:FUN), andSeaWorld Entertainment(NYSE:SEAS)joined the theme park segments of Disney (NYSE:DIS) and Comcast (NASDAQ:CMCSA) in posting double-digit revenue growth in the latest quarter.

  • [By Rick Munarriz]

    Investors were ready for SeaWorld Entertainment(NYSE:SEAS)to post its strongest growth in five years on Tuesday morning, and they got a whole lot more. Shares of the marine-life park operator are hitting 11-month highs after the company announced head-turning financial results.

Best Safest Stocks To Invest In 2019: Saratoga Investment Corp(SAR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Shares of Saratoga Investment Corp (NYSE:SAR) reached a new 52-week high and low on Friday after an insider bought additional shares in the company. The stock traded as low as $22.95 and last traded at $22.85, with a volume of 650 shares. The stock had previously closed at $22.70.

  • [By Logan Wallace]

    ValuEngine downgraded shares of Saratoga Investment (NYSE:SAR) from a buy rating to a hold rating in a research report released on Wednesday.

    A number of other analysts have also issued reports on the stock. National Securities reiterated a neutral rating and set a $24.00 price target (up from $23.00) on shares of Saratoga Investment in a research note on Friday, January 12th. Zacks Investment Research lowered shares of Saratoga Investment from a hold rating to a sell rating in a research note on Friday, March 2nd. Finally, B. Riley initiated coverage on shares of Saratoga Investment in a research note on Tuesday, March 27th. They set a buy rating and a $23.50 price target on the stock. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Saratoga Investment presently has a consensus rating of Buy and an average price target of $24.38.

  • [By Max Byerly]

    Headlines about Saratoga Investment (NYSE:SAR) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Saratoga Investment earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the financial services provider an impact score of 45.4912059514825 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Saratoga Investment (SAR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Somewhat Positive Press Coverage Somewhat Unlikely to Affect Celgene (CELG) Stock Price

Media stories about Celgene (NASDAQ:CELG) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Celgene earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.8752042911031 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

Get Celgene alerts:

Tower Semiconductor, Celgene Drop into Monday’s 52-Week Low Club (247wallst.com) Celgene Just Caught A Major Break From The FDA For Multiple Sclerosis Drug (seekingalpha.com) Celgenes Revlimid Witnessed Solid Growth in 1Q18 (finance.yahoo.com) CELG EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene … (businesswire.com) Edited Transcript of CELG earnings conference call or presentation 4-May-18 1:00pm GMT (finance.yahoo.com)

CELG has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the company a “hold” rating in a report on Monday, January 8th. Oppenheimer set a $166.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Monday, January 8th. Deutsche Bank set a $110.00 price target on shares of Celgene and gave the company a “hold” rating in a report on Monday, January 8th. Stifel Nicolaus set a $130.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Monday, January 8th. Finally, Credit Suisse Group set a $125.00 price target on shares of Celgene and gave the company a “buy” rating in a report on Monday, January 8th. Three research analysts have rated the stock with a sell rating, twelve have issued a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $123.98.

CELG stock traded down $1.44 during mid-day trading on Tuesday, hitting $83.13. 6,630,174 shares of the company were exchanged, compared to its average volume of 7,481,783. The firm has a market cap of $63.11 billion, a P/E ratio of 12.15, a P/E/G ratio of 0.58 and a beta of 1.49. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80. Celgene has a twelve month low of $82.60 and a twelve month high of $147.17.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Friday, May 4th. The biopharmaceutical company reported $2.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.96 by $0.09. The company had revenue of $3.54 billion during the quarter, compared to analyst estimates of $3.47 billion. Celgene had a net margin of 20.73% and a return on equity of 65.90%. The firm’s revenue for the quarter was up 19.4% compared to the same quarter last year. During the same period last year, the business earned $1.68 EPS. sell-side analysts expect that Celgene will post 7.69 EPS for the current year.

Celgene declared that its Board of Directors has authorized a stock buyback program on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to purchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

In other news, Director James J. Loughlin sold 9,250 shares of Celgene stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $92.01, for a total value of $851,092.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark J. Alles purchased 3,260 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was acquired at an average cost of $91.90 per share, with a total value of $299,594.00. Following the completion of the acquisition, the insider now directly owns 178,904 shares in the company, valued at approximately $16,441,277.60. The disclosure for this purchase can be found here. Insiders sold a total of 41,120 shares of company stock valued at $3,879,509 over the last ninety days. Company insiders own 0.95% of the company’s stock.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Insider Buying and Selling by Quarter for Celgene (NASDAQ:CELG)

Are These 2 Biotech Laggards Ready to Rebound?

Biotech hasn’t been a great place to invest your money in 2018.The iShares Nasdaq Biotechnology Index, after all, is down by over 4% at present, and summer has historically been a down time for this high-risk space. So, there’s little reason to believe a widespread rally is coming anytime soon.

Even against this dour backdrop, however, several former top biotech stocks have turned out to be particularly disappointing investing vehicles this year. Acadia Pharmaceuticals (NASDAQ:ACAD) and Celgene Corporation (NASDAQ:CELG), for instance, are both trading near their 52-week lows right now. That’s a surprising turn of events given that Acadia and Celgene were two of the absolute best-performing growth stocks since about the start of 2010.

Man in a business suit facing a wall with several white arrows pointing one direction and a single yellow arrow pointing in the opposite direction.

Image source: Getty Images.

Should investors take advantage of this weakness in these two former highfliers? Let’s dig deeper to find out.

Is Acadia’s risk overstated?

Acadia stock has suffered from two interrelated issues this year. First off, the company’s valuation at the start of the year seemed to reflect an unwarranted optimism surrounding the commercial potential of Nuplazid, Acadia’s FDA-approved drug for Parkinson’s disease psychosis (PDP).

In short, investors were clearly expecting Nuplazid to achieve blockbuster status almost right out of the gate. As the drug has a questionable risk-to-reward ratio, however, it’s not all that surprising that Nuplazid has so far failed to live up to these lofty expectations.

And the drug’s murky risk-to=reward ratio is at the heart of the company’s second major issue. A recent report by CNN suggested that Nuplazid’s substantial risks outweigh its modest rewards, which, in turn, caused the FDA to take a deeper look at the drug’s emerging safety profile since coming on the market.

Although the FDA is unlikely to pull Nuplazid for a variety of reasons, investors are still concerned about this existential threat. Nuplazid, after all, is Acadia’s only product, and it doesn’t have much of a clinical pipeline to fall back on.

On the bright side, Acadia’s management has stuck by its annual 2018 sales guidance for Nuplazid of between $255 million and $270 million, and the company has been adamant about its position that this drug is an important new treatment option for PDP.

The core problem here, though, is that Acadia’s valuation is still way out of line with its peers — even after this year’s downward move. At present, Acadia’s shares are trading at a forward price-to-sales ratio of 7.9 at the high end of its estimated revenue guidance. The historical average for biotechs with traditional small-molecule drugs like Nuplazid, by contrast, is closer to 6.

With a possible black swan event lurking in the shadows (Nuplazid getting pulled from the market), it’s hard to justify buying this stock right now. At best, Acadia’s shares are now only slightly overvalued, and a buyout scenario appears to be moot issue with Nuplazid’s current regulatory risk.

Can Celgene overcome these missteps?

Celgene stock has plunged this year due to the unexpected regulatory setback for its multiple sclerosis drug candidate ozanimod, as well as the questionable acquisitions of Impact Biomedicines and Juno Therapeutics that cut deeply into the biotech’s cash reserves. The long and short of it is that Celgene is under immense pressure to find an heir apparent to its flagship multiple myeloma drug Revlimid.

Now, ozanimod was supposed to be that drug, given its potential to generate upwards of $6 billion in peak sales. With the drug’s commercial launch delayed by at least a year, however, ozanimod could end facing a far tougher competitive landscape by the time it finally hits the market.

And that’s why Celgene’s management was quick to note the sizable commercial potential of Juno’s and Impact’s lead product candidates — JCAR017 andfedratinib respectively — during itsfirst-quarter conference call last week. Unfortunately, these two product candidates do have their own set of unique problems that could significantly dampen their commercial prospects, too.

Overall, the picture that’s emerging with Celgene is a company that’s lost its way to some degree. The ozanimod fiasco triggered a change in key leadership positions, and the biotech’s acquisitions of Juno and Impact appear, in hindsight, to be questionable moves at best. Valued at a mere 8.55 times forward earnings, though, Celgene stock is probably worth the risk at these levels.

Are these two stocks worth owning right now?

Acadia could be in for some dark days in the near future. There’s no telling what the ultimate fallout from that CNN report regarding Nuplazid’s risk-to-reward ratio will be, and there’s now the remote chance that the FDA could even pull the drug from the market. As such, this speculative biotech stock arguably isn’t worth the potential headaches that could come with owning it.

Celgene, on the other hand, probably deserves the benefit of the doubt. The company has made some regrettable errors this year, but management has been proactive at dealing with them head-on.The company also has a top-notch clinical pipeline that should be able to keep the growth going for at least another five to 10 years — even if Juno and Impact both fail to live up to expectations. So with Celgene’s shares trading at rock-bottom prices from a historical perspective, investors may want to consider taking advantage and scooping up some shares.

Top Medical Stocks To Own For 2018

&l;p&g;&l;img class=&q;dam-image ap size-large wp-image-ba4ef5ff096448cd8ab8d96d86dd3669&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/ba4ef5ff096448cd8ab8d96d86dd3669/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Diana Briggs, whose son, Ryan Briggs suffers from intractable epilepsy, leaves CY+ Medical marijuana Dispensary with a bag containing the medicine for him after being the first patron to buy a prescribed medical marijuana product at a dispensary on Thursday, Feb. 15, 2018 in Butler, Pa.(AP Photo/Keith Srakocic)

While it&s;s not a done deal until Congress formally approves it and President Trump signs it, the &l;a href=&q;https://www.politico.com/f/?id=00000162-4b0d-de1c-abfe-6bbd26030001&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;budget proposal&l;/a&g; agreed to by Congressional leaders last night&a;nbsp;would keep medical cannabis protections in effect through September 30, as fellow &l;em&g;Forbes&l;/em&g;&a;nbsp;contributor Tom Angell &l;a href=&q;https://www.forbes.com/sites/tomangell/2018/03/21/congress-protects-medical-marijuana-from-jeff-sessions-in-new-federal-spending-bill/#1d62e0b43575&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q;&g;noted last night&l;/a&g;. As I shared two months ago, the rescission of the Cole Memo in early January by Attorney General Jeff Sessions had left the industry &l;a href=&q;https://www.forbes.com/sites/alanjbrochstein/2018/01/21/cannabis-stock-investors-should-pay-attention-to-the-u-s-federal-policy-change/#39e7e0273788&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q;&g;vulnerable to federal enforcement of the Controlled Substances Act&l;/a&g;&a;nbsp;if the Rohrabacher-Blumenauer Amendment were not to be included in the next budget. My caution on cannabis stocks has been warranted, as the &l;a href=&q;https://www.newcannabisventures.com/cannabis-stock-index/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;Global Cannabis Stock Index&l;/a&g; has sold off more than 27% over the past two months since my warning.

Top Medical Stocks To Own For 2018: Performant Financial Corporation(PFMT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Performant Financial Corporation (NASDAQ: PFMT) were down 29 percent to $2.20. Performant Financial is expected to release Q1 earnings on May 8.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    Check-Cap Ltd. (NASDAQ: CHEK) shares dipped 47.8 percent to $4.60. Check-Cap priced its upsized underwritten offering of public units at $5.50 per unit.
    VivoPower International PLC (NASDAQ: VVPR) shares fell 41.5 percent to $2.57.
    Universal Electronics Inc. (NASDAQ: UEIC) dropped 35.1 percent to $29.50 after the company posted downbeat quarterly results.
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) dropped 34.8 percent to $3.75 after climbing 155.56 percent on Thursday.
    Integrated Media Technology Limited (NASDAQ: IMTE) fell 25.2 percent to $24.01 after surging 46.29 percent on Thursday.
    Fluor Corporation (NYSE: FLR) dropped 22.5 percent to $45.73 after the company reported downbeat earnings for its first quarter and lowered its profit outlook for the year.
    AMN Healthcare Services, Inc (NYSE: AMN) shares fell 19.6 percent to $52.075 following Q1 earnings.
    Adverum Biotechnologies, Inc. (NASDAQ: ADVM) shares declined 18.1 percent to $5.20. Adverum Biotech disclosed that its CEO Amber Salzman is stepping down.
    Newater Technology, Inc. (NASDAQ: NEWA) dropped 17.2 percent to $12.83.
    Basic Energy Services, Inc. (NYSE: BAS) fell 17.2 percent to $13.65 following Q1 results.
    Xperi Corporation (NASDAQ: XPER) declined 15.8 percent to $19.40 after announcing Q1 results.
    Sharing Economy International Inc. (NASDAQ: SEII) shares fell 15.1 percent to $3.649 after climbing 22.16 percent on Thursday.
    Performant Financial Corporation (NASDAQ: PFMT) dropped 14.2 percent to $2.65.
    Gogo Inc. (NASDAQ: GOGO) shares fell 13.2 percent to $8.32 after the company reported Q1 results and disclosed that it is withdrawing its FY18 outlook for adjusted EBITDA, airborne cash capex, airborne equipment inventory purchases and free cash flow.
    Technical Communications Corporation (NASDAQ: TCCO) dropped 12.2 percent to $5.05.
    Web.com Group, Inc. (NASDAQ: WEB) fell 9.7 percent

Top Medical Stocks To Own For 2018: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
    Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
    American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
    Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
    LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
    V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
    Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
    Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
    Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
    Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
    Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
    ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
    Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
    Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
    Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
    Genesis Energy, L.P
  • [By WWW.THESTREET.COM]

    Originally published Nov. 17 at 3:41 p.m. EDT

    The consideration of the contrary has been a theme all week. And here in ” Don’t Run With the Crowd: Embrace the Contrary.”   Miami madness (of a real estate kind)   Mark Grant is scared by our currency’s strength.   Danielle on scenarios.   Boockvar to subscriber Bad Golfer!   JC Penney ( JCP) short puts–a 100% win. (Shorting options frequently ends differently!)   Just say no to closed-end muni-bond funds.   DRYS is all wet.   Could iPhone manufacturing be coming back home?   On inflation breakevens–a picture that speaks volumes.   The market moved higher from the “get go”–in large measure it seems to be a response to the better economic data this morning.   At 3 p.m. stocks were near the day’s highs.   I shorted The Cisco Kid last night. Sticking with this short rental. I added to my ProShares UltraShort S&P500 ETF ( SDS) long (growing ever larger). My net short exposure–is now between small and medium-sized at the close. The U.S. dollar, as discussed above, continued to rip higher against the euro. I am concerned. Mark Grant is concerned. The market is not concerned. The price of crude oil (down $0.20) settled lower after yesterday’s robust gains. Gold fell $9 as it continues to break down–closing in on $1,200. Ag commodities: wheat up $0.07, corn up $0.04, soybeans up $0.05 and oats up $0.02. Lumber up $7 following the big housing number this morning. Bonds schmeissed … iShares Barclays 2

  • [By Keith Speights]

    That’s a pretty good definition of leadership, but it’s not an easy one to accomplish. However, the CEOs of Celgene (NASDAQ:CELG), Cognizant Technology Solutions (NASDAQ:CTSH), General Electric (NYSE:GE), MasterCard (NYSE:MA), and Texas Instruments (NASDAQ:TXN) have been able to achieve this translation very well.

  • [By Keith Speights]

    Smart investors will be ready to take advantage of a market pullback, whenever it comes and offers discount prices on great stocks. Three drug stocks appear to be excellent choices to buy on a dip: AbbVie (NYSE:ABBV), Allergan (NYSE:AGN), and Celgene (NASDAQ:CELG). Here’s why.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

Top Medical Stocks To Own For 2018: Vermillion, Inc.(VRML)

Advisors’ Opinion:

  • [By Alex McGuire]

    Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…

    Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%

    The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.

Top Medical Stocks To Own For 2018: Transdigm Group Incorporated(TDG)

Advisors’ Opinion:

  • [By Ben Levisohn]

    TransDigm Group (TDG) soared to the top of the S&P 500 today after beating earnings and sales forecasts.

    Agence France-Presse/Getty Images

    TransDigm gained 6.5% to $245.88 today, while the S&P 500 finished little changed at2,293.08.

    TransDigm reported a profit of $2.57, beating forecasts for$2.47, on sales of $814 million, topping the Street consensus for $804.5 million.

    TransDigm’s market capitalization rose to $13.1 billion today from $12.3 billion yesterday.

  • [By Mitchell Clark]

     This firm is not a household name. This Cleveland-based company, in the aerospace parts business, has approximately $12.0 billion in market capitalization on the stock market.

    TransDigm Group Incorporated (NYSE:TDG) doesn’t pay a regular dividend, but often pays out one-time, special dividends. In the past, they’ve been pretty hefty.

    Selling pumps, motors, power systems, and basically anything you can image that’s part of an aircraft, TDG’s been growing its financial results at a good clip.

  • [By Ben Levisohn]

    TransDigm Group (TDG) tumbled to the bottom of the S&P 500 today after Citron Research doubled down on its assertion that the company is a manufacturing version of Valeant Pharmaceuticals International (VRX).

    Agence France-Presse/Getty Images

    TransDigm Groupdropped 4.2% to $231.37, while the S&P 500 rose 0.3% to 2,372.60.

    From Citron’s report on TransDigm:

    Citron predicts that after this report makes its rounds, TransDigms (NYSE:TDG) days of exploiting and deceiving the Federal Government are numbered.

    Valeant Pharmaceuticals has recently hit prices lower than some ever thought was imaginable. As Citron observes today, at $12 per share, that stock is down over 95% from its highs just months prior to Citrons reporting on Philidor. The questions then turn to: How did so many smart people get it so wrong? and When could this possibly happen again?”

    While we are sure there will be many books written on these questions, we can narrow it down to a small checklist. The smart money got Valeant wrong by:

    Disregarding a roiling political climate disrupting “business as
    usual” Underestimating the financial frailty of a roll up Discounting the dangers of a small customer base (PBMs) Putting too much trust in the companys CEO…

    All points in the above checklist apply directly to TransDigm.

    TransDigm Group’s market capitalization fell to $12.2 billion today from $12.8 billion yesterday. It reported net income of $583 million on sales of $3.2 billion in 2016.

  • [By Ben Levisohn]

    TransDigm (TDG) sunk to the bottom of the S&P 500 today after its earnings topped the Street consensus but its guidance disappointed.

    Shares of TransDigm fell 7.1% to $$252.96 today, while the S&P 500 finished little changed.

    TransDigm reported a profit of $3.29 a share, better than the $3.20 expect by analysts, on sales of$875.2 million, below forecasts for $884.26 million. Worse still, the airplane-part manufacturer said it would earn $11.84 to $12.12 a share in fiscal 2017, below forecasts for$12.80.

    TransDigm’s market cap fell to $13.5 billion today, from $14.5 billion on Friday.

  • [By Lee Jackson]

    Transdigm Group Inc. (NYSE: TDG) had a director at the company step in and buy stock in a big way last week. That director purchased a total of 91,000 shares of the stock at prices ranging from $247.16 to $247.89. The total for the trade came in near $22.7 million.The company designs, produces and supplies aircraft components in the United States. Its stock closed trading last Friday at $251.488.

  • [By Lee Jackson]

    Warren Buffett and Berkshire Hathaway were big buyers this week, as they added shares of aircraft components maker Transdigm Group Inc. (NYSE: TDG), forwhich they also serve as a director. Berkshire Hathaway bought 104,967 shares of the stock at prices that ranged from $231.18 to $234.40 per share. The total for the trade came in at a massive $25 million. The shares closed trading last Friday at $240.05, so the timing looks good. The 52-week trading range for the stock is $214.65 to $294.38. The Wall Street consensus price target is pegged at $295.24.

Top Medical Stocks To Own For 2018: CVD Equipment Corporation(CVV)

Advisors’ Opinion:

  • [By Jim Robertson]

    On Wednesday, our Under the Radar Moversnewsletter suggested small cap materials and coatings stock CVD Equipment Corporation (NASDAQ: CVV) as a short/bearish trade:

  • [By Jim Robertson]

    At the beginning of the week, our Under the Radar Moversnewsletter suggestedsmall cap industrial machinery stock CVD Equipment Corporation (NASDAQ: CVV) as a long/bullish trade:

Top Medical Stocks To Own For 2018: Rackspace Hosting Inc(RAX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Rackspace Hosting, Inc. (NYSE: RAX) reported better-than-expected earnings for the first quarter, but the company missed analysts’ sales estimates. Rackspace shares dropped 7.72 percent to $20.80 in the after-hours trading session.

Earnings Scheduled For May 4, 2018

Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
Genesis Energy, L.P. (NYSE: GEL) is estimated to report quarterly earnings at $0.32 per share on revenue of $710.05 million.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) is projected to report quarterly earnings at $0.92 per share on revenue of $524.05 million.
CenterPoint Energy, Inc. (NYSE: CNP) is estimated to report quarterly earnings at $0.43 per share on revenue of $2.63 billion.
Buckeye Partners, L.P. (NYSE: BPL) is projected to report quarterly earnings at $0.81 per share on revenue of $911.27 million.
LCI Industries (NYSE: LCII) is estimated to report quarterly earnings at $1.94 per share on revenue of $618.32 million.
Denbury Resources Inc. (NYSE: DNR) is expected to report quarterly earnings at $0.11 per share on revenue of $312.75 million.
W. P. Carey Inc. (NYSE: WPC) is estimated to report quarterly earnings at $0.53 per share on revenue of $170.81 million.
Triton International Limited (NYSE: TRTN) is expected to report quarterly earnings at $0.92 per share on revenue of $329.70 million.
New Jersey Resources Corporation (NYSE: NJR) is estimated to report quarterly earnings at $0.97 per share on revenue of $749.71 million.
Johnson Outdoors Inc. (NASDAQ: JOUT) is expected to report quarterly earnings at $1.47 per share on revenue of $159.18 million.

 

Companies Reporting After The Bell
BWX Technologies, Inc. (NASDAQ: BWXT) is estimated to post quarterly earnings at $0.61 per share on revenue of $442.30 million.
Weyco Group, Inc. (NASDAQ: WEYS) is expected to post earnings for its first quarter.

Top Warren Buffett Stocks To Own Right Now

Billionaire investor Warren Buffett sees the value of Apple differently than most Wall Street analysts, CNBC’s Jim Cramer said Friday.

“Analysts after analysts said if you look at the mosaic of [iPhone] orders, it’s got to be a bad quarter,” said Cramer, whose charitable trust owns shares of Apple. “[Buffett] obviously does not think about the quarter. He thinks of this as a consumer products company with 99 percent satisfaction.”

“[Buffett] thinks very young,” Cramer said on “Squawk on the Street.” He often talks about “how every kid he knows has one and they would never use anything else. That’s good enough for him.”

Apple stock rose more than 3 percent Friday to an all-time high midmorning Friday after Buffett revealed that Berkshire Hathaway bought 75 million shares of the tech giant during the first quarter. That adds to the 165.3 million shares Berkshire already owned at the end of 2017.

Top Warren Buffett Stocks To Own Right Now: AFC Enterprises Inc.(AFCE)

Advisors’ Opinion:

  • [By AnnaLisa Kraft]

    AFC Enterprises (NASDAQ: AFCE  ) , which owns the Popeye’s Louisiana Kitchen quick- serve chain, once an undiscovered gem, has now soared 66% over the last year.

Top Warren Buffett Stocks To Own Right Now: WSFS Financial Corporation(WSFS)

Advisors’ Opinion:

Top Warren Buffett Stocks To Own Right Now: Celgene Corporation(CELG)

Advisors’ Opinion:

  • [By Lisa Levin]

    Some of the stocks that may grab investor focus today are:

    Wall Street expects Celgene Corporation (NASDAQ: CELG) to report quarterly earnings at $1.96 per share on revenue of $3.46 billion before the opening bell. Celgene shares rose 1.87 percent to $87.00 in after-hours trading.
    Weight Watchers International, Inc. (NYSE: WTW) reported stronger-than-expected results for its first quarter. The company also raised its FY18 earnings outlook from $2.40-$2.70 to $3-$3.20. Weight Watchers shares gained 7.36 percent to $74.83 in the after-hours trading session.
    Analysts are expecting Alibaba Group Holding Limited (NYSE: BABA) to have earned $0.88 per share on revenue of $9.27 billion in the latest quarter. Alibaba will release earnings before the markets open. Alibaba shares fell 0.68 percent to $181.21 in after-hours trading.
    GoPro Inc (NASDAQ: GPRO) reported better-than-expected results for its first quarter on Thursday. GoPro shares fell 1.41 percent to $4.89 in the after-hours trading session.
    Before the markets open, American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is projected to report quarterly earnings at $0.81 per share on revenue of $1.75 billion. American Axle shares gained 1.05 percent to $14.50 in after-hours trading.

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

  • [By Chris Lange]

    Celgene Corp.s (NASDAQ: CELG) short interest for this settlement date remained flat at 15.65 million shares. Shares were changing hands at $89.14, in a 52-week trading range of $84.25 to $147.17.

  • [By WWW.THESTREET.COM]

    Celgene (CELG) : “Celgene’s a buy, I think it’s terrific.”

    Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener.

  • [By WWW.THESTREET.COM]

    Position: Long GLD small, bonds, SDS; short TLT small, SPY small .

Top Warren Buffett Stocks To Own Right Now: Yum! Brands, Inc.(YUM)

Advisors’ Opinion:

  • [By ]

    These figures should be a relief for Niccol, who joined the company from Yum! Brands’ (YUM) Taco Bell in February. While he was largely welcomed by investors and received industry affirmation, some critics were skeptical of his franchising background, operational savvy and the disparity in ethos between Chipotle and Taco Bell.

  • [By WWW.GURUFOCUS.COM]

    McDonald’s is a fast-food service restaurant with more than 36 thousand restaurants in around 100 countries. With a market cap of $100 billion, the company has the largest position in the fast-food industry in the U.S., with Yum Brands (NYSE:YUM) being its closest competitor. The company sells burgers, fries and sandwiches with the vision of providing great taste, modern choices and real ingredients. McDonald’s is constantly trying to find new ways to strengthen the nutritional profile of its menu items while maintaining taste.

  • [By Nicholas Rossolillo]

    Pizza Hut, on the other hand, took a step back after rebounding at the end of 2017. Total sales dropped 1%, driven by a 5% decline in same-store sales and slightly offset by 109 more locations in operation than last year. Pizza Hut has had its struggles the last few years in China. Pizza doesn’t carry the same status as a dietary staple in the country as it does here in the U.S. Yum has been trying to change that by innovating the menu around local tastes, but it reports that the strategy will take some more time before its efforts can be judged. Yum China only gained independence from former parentYum! Brands(NYSE:YUM) at the end of 2016.

  • [By Daniel B. Kline]

    While its closest rivals Domino’s (NYSE:DPZ) and Papa John’s (NASDAQ:PZZA) have steadily delivered impressive growth in the United States Yum! Brands (NYSE:YUM) Pizza Hut has struggled.

Fridays Vital Data: Intel Corporation (INTC), NXP Semiconductors N.V. (NXPI) and Alibaba Group Ho

U.S. stock futures are trading broadly lower this morning. Wall Street was clearly anxious ahead of this morning’s April jobs report. Expectations were for a gain of 188,000 last month, on the heels of March’s surprisingly low 108,000 job adds.

stock market today

Meanwhile, corporate earnings continue to chug along. Alibaba Group Holding Ltd (NYSE:BABA), Celgene Inc. (NASDAQ:CELG) and GoPro Inc. (NASDAQ:GPRO) are front and center on the earnings front.

Heading into the open, futures on the Dow Jones Industrial Average are down 0.33%, S&P 500 futures have shed 0.35% and Nasdaq-100 futures have lost 0.42%.

Turning to the options pits, volume rebounded to normal levels on Thursday. Overall, about 19.9 million calls 18.8 million puts crossed the tape. Despite the jump in call activity, the CBOE single-session equity put/call volume ratio surged to a one-month high of 0.75. The 10-day moving average also moved higher, hitting it’s own one-month high of 0.66.

Options traders were once again paying sharp attention to the semiconductor sector. News broke that “next generation” flaws were again found in Intel Corporation (NASDAQ:INTC) chips, driving heavy volume on INTC stock. Additionally, NXP Semiconductors N.V. (NASDAQ:NXPI) reported weaker-than-expected earnings, drawing attention to options arbitrage spreads in it’s Qualcomm Inc. (NASDAQ:QCOM) merger deal. Finally, Alibaba Group Holdings was call heavy heading into this morning’s quarterly earnings report.

Let’s take a closer look:

Friday’s Vital Options Data: Intel Corporation (INTC), NXP Semiconductors N.V. (NXPI) and Alibaba Group Holding Ltd (BABA)investorplace.com/wp-content/uploads/2018/05/05-04-2018-Top-Ten-Options-300×136.png 300w, investorplace.com/wp-content/uploads/2018/05/05-04-2018-Top-Ten-Options-200×90.png 200w, investorplace.com/wp-content/uploads/2018/05/05-04-2018-Top-Ten-Options-400×181.png 400w, investorplace.com/wp-content/uploads/2018/05/05-04-2018-Top-Ten-Options-116×52.png 116w, investorplace.com/wp-content/uploads/2018/05/05-04-2018-Top-Ten-Options-100×45.png 100w, investorplace.com/wp-content/uploads/2018/05/05-04-2018-Top-Ten-Options-111×50.png 111w,https://investorplace.com/wp-content/uploads/2018/05/05-04-2018-Top-Ten-Options-78×35.png 78w” sizes=”(max-width: 518px) 100vw, 518px” />

Intel Corporation (INTC)

Options traders loaded up on Intel calls yesterday. It was an interesting reaction to news that “next generation” flaws had been found in Intel semiconductors. Specifically, a German computing magazine reported yesterday that researchers found eight new flaws in INTC chips resembling the Meltdown and Spectre bugs revealed earlier this year.

Intel said it was aware of the flaws and was working to patch them. “We believe strongly in the value of coordinated disclosure and will share additional details on any potential issues as we finalize mitigations,” Intel said in a statement.

In a “been there, done that” kind of response, INTC options traders loaded up on call options following the news. Volume came in at 177,000 contracts, with calls gobbling up 83% of the day’s take.

Looking out to May options, the bulls appear to be in firm control of Intel’s short-term sentiment backdrop. Currently, the May put/call open interest ratio comes in at 0.45, with calls more than doubling puts for the series.

But this Intel optimism is not without merit. In fact, INTC stock continues to outperform most of its semiconductor peers, including red-hot names like Advanced Micro Devices, Inc. (NASDAQ:AMD) and Micron Technology Inc. (NASDAQ:MU).

Compare Brokers

NXP Semiconductors N.V. (NXPI)

If you are arbitraging Qualcomm’s buyout of NXP Semiconductors, yesterday was painful for you. NXPI stock plunged more than 10% after the company missed Wall Street’s first-quarter earnings target by 12 cents per share. NXPI is now trading about 36% below Qualcomm’s buyout offer of $127.50 per share.

The deal has been slowed by Chinese regulators, whom many argue are dragging their feet due to troubled China/U.S. trade relations.

NXPI options traders were somewhat bullish following the news. Volume rose to 190,000 contracts, nearly tripling NXPI’s daily average. Calls made up about 58% of the day’s take. But while short-term options are optimistic, August options are downright bearish.

Qualcomm and NXP expect a ruling from China by their new deal deadline of July 25. If the August put/call OI ratio of 1.80 is any indication, NXPI options traders believe the deal will fall apart.

Alibaba Group Holding Ltd (BABA)

Alibaba calls were quite popular ahead of this morning’s quarterly report. Volume rose to an impressive 406,000 contracts, with calls eating up 71% of the day’s take. As a result, the May put/call OI ratio fell to 0.67 as traders bet on a post-earnings rally.

Heading into the open, BABA stock is up 1.5% amid a weak start among the major market indexes.

By the numbers, Alibaba posted another blowout quarter. Earnings rose 32% year-over-year to 90 cents per share, topping expectations by 5 cents per share. Sales surged 61% to $9.73 billion, easily beating Wall Street’s view for $9.3 billion.

As of this writing, Joseph Hargett held no positions on any of the aforemen